CN113429471B - Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof - Google Patents

Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof Download PDF

Info

Publication number
CN113429471B
CN113429471B CN202110815583.3A CN202110815583A CN113429471B CN 113429471 B CN113429471 B CN 113429471B CN 202110815583 A CN202110815583 A CN 202110815583A CN 113429471 B CN113429471 B CN 113429471B
Authority
CN
China
Prior art keywords
gly
ser
glu
polypeptide
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110815583.3A
Other languages
Chinese (zh)
Other versions
CN113429471A (en
Inventor
孟静
蒋秀苹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Borui Jingchuang Technology Co ltd
Original Assignee
Qingdao Borui Jingchuang Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Borui Jingchuang Technology Co ltd filed Critical Qingdao Borui Jingchuang Technology Co ltd
Priority to CN202110815583.3A priority Critical patent/CN113429471B/en
Priority to CN202211555764.8A priority patent/CN116554299A/en
Priority to CN202211555750.6A priority patent/CN116410297A/en
Priority to PCT/CN2021/107770 priority patent/WO2023000240A1/en
Publication of CN113429471A publication Critical patent/CN113429471A/en
Application granted granted Critical
Publication of CN113429471B publication Critical patent/CN113429471B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention belongs to the technical field of biochemistry, and particularly relates to a long-acting GLP-1 polypeptide analogue for treating or preventing diabetes or obesity, and a preparation method and application thereof. Solves the problems of short half-life period and insufficient metabolic stability of complex polypeptide. The amino acid sequence structure of the long-acting GLP-1 polypeptide analogue of the invention is as follows: the 20 th Lys is connected with a short peptide chain of a side arm in a mode of: the amino group of the short peptide chain of the side arm of the Lys at the 20 th position and the carboxyl group of the glycine of the short peptide chain of the side arm form an amido bond; the amino acid of the end Z of the short peptide chain of the side arm is connected with a fatty acid substituent. The long-acting GLP-1 polypeptide analogue has the advantages of long half-life period, high synthesis yield, good stability, easy amplification production and low cost, and has good drug effect on treating diabetes and reducing weight.

Description

Long-acting GLP-1 polypeptide analogue and preparation method and application thereof
Technical Field
The invention belongs to the technical field of biochemistry, and particularly relates to long-acting GLP-1 polypeptide analogues for treating or preventing diabetes or obesity, and a preparation method and application thereof.
Background
Diabetes is a chronic disease in which the body is at high blood sugar level for a long time to cause sugar metabolism disorder of the body, and the disease is mainly characterized in that: chronic hyperglycemia, and at the same time insulin secretion deficiency or insulin dysfunction, further causes chronic damage to various organs by affecting the metabolism of fats, carbohydrates and proteins, resulting in gradual organ dysfunction and even organ failure.
Over the past three decades, the number of diabetics worldwide has increased by three times. Worldwide, nearly 9% of adults suffer from type 2 diabetes (T2 DM). The advent of T2DM and its complications has greatly exacerbated the worldwide risk of disability and death. For example, the "2013 global risk for disease study" identified diabetes (all forms) as the ninth leading cause of decreased life expectancy. Based on the results of many investigations, it has been shown that diabetes is not effectively controlled in developed countries in europe and america, or in developing countries like china. Diabetes has become another important chronic non-infectious disease seriously endangering human health after cardiovascular and cerebrovascular diseases and tumors.
Obesity and diabetes belong to metabolic diseases, and are closely related to the occurrence of diabetes. Diabetes is mainly caused by the decline of islet beta cell function and insulin resistance, and obesity is a key factor of insulin resistance. The obesity patient is easy to generate insulin resistance due to excessive weight and high fat content, and the insulin resistance can not enable insulin in the body to play a corresponding role in reducing blood sugar. Insulin is the only blood sugar-lowering hormone in the body, the body must increase the insulin secretion capacity of islet beta cells for controlling blood sugar, and diabetes can occur when the blood sugar is still not normal due to the increase of insulin secretion, so that obesity is the root cause of insulin resistance and is also an important reason for the occurrence of diabetes.
An interesting phenomenon observed in McIntyre and ellick et al in the 60's of the 20 th century, the promotion of insulin secretion by oral glucose was significantly higher than that by intravenous injection, an effect known as the "incretin effect", and glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-releasing peptide (GIP) were subsequently found in extracts of the small intestinal mucosa. GLP-1 is a hormone that induces insulin secretion and has beneficial effects on a variety of vital organs including pancreas, heart, liver, etc. GLP-1 receptor (GLP-1R) agonist drugs have the advantages of effectively controlling blood sugar, obviously reducing incidence rate of hypoglycemic events, obviously reducing weight and reducing risk of cardiovascular events. However, due to the characteristics of a specific polypeptide structure of the GLP-1 medicament, the GLP-1 medicament has instability, can be degraded by gastric acid after being orally taken, can be basically administrated only by subcutaneous injection, and has short half life.
With the intensive research on diabetes and the treatment thereof, GLP-1 receptor agonists such as liraglutide, somaglutide and the like have been approved for marketing in recent years. Wherein, the affinity of the increased carbon chain of the somagluteptide to albumin is greatly enhanced, and the elimination of the somagluteptide to albumin is greatly slowed down. The two reconstruction parts prolong the half-life period of the rat to about 8h, and only one subcutaneous injection is needed clinically every week.
Nevertheless, how to solve the problems of short half-life and insufficient metabolic stability of polypeptides, especially complex polypeptides, in a breakthrough manner remains a major scientific and core problem in the field; the development of the ultra-long-acting polypeptide drug molecule modification technology is a key and is also a bottleneck to be broken through internationally in the field of research.
Disclosure of Invention
In view of the above problems, it is an object of the present invention to provide a new class of GLP-1 polypeptide analogues with a longer duration.
It is a further object of the present invention to provide a method for the preparation of such long-acting GLP-1 polypeptide analogues.
It is a further object of the present invention to provide a composition comprising the above-described long-acting GLP-1 polypeptide analog.
Still another object of the present invention is to provide uses of the above GLP-1 polypeptide analogs.
According to a specific embodiment of the invention, the long-acting GLP-1 polypeptide analogue has the following amino acid sequence:
His-Xaa2-Glu-Gly-Thr-Phe-Thr-Ser-Xaa9-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys{(Gly) x -(Ser-Gly) y -Z-CO(CH 2 ) n CO 2 H}-Xaa21-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
wherein:
xaa2 is Aib or D-Ser;
xaa9 is Asp or Glu;
xaa21 is Glu or Gln or Asp;
z is gamma Glu or Asp;
x is 1, 2, 3 or 4;
y is 1, 2, 3 or 4;
n is an integer from 12 to 20, i.e. n is 12, 13, 14, 15, 16, 17, 18, 19 or 20.
Wherein, the first and the second end of the pipe are connected with each other,
His-Xaa2-Glu-Gly-Thr-Phe-Thr-Ser-Xaa9-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Xaa21-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly as main peptide chain;
(Gly) x -(Ser-Gly) y -Z-CO(CH 2 ) n CO 2 h is a side arm structure;
the side arm structure comprises a side arm short peptide chain- (Gly) x- (Ser-Gly) y-Z-and a fatty acid substituent-CO (CH) connected with the side arm short peptide chain- (Gly) 2 ) n CO 2 H。
The side chain amino of the 20 th Lys in the main peptide chain amino acid sequence is connected with a side arm short peptide chain structure in an amido bond mode formed by the side chain amino and the carboxyl of the other end glycine residue;
further, the amino group of the "Z" amino acid residue at the end of the "side arm" short peptide chain is linked to a fatty acid substituent by forming an amide bond with a carboxyl group.
The carboxyl terminal of the main peptide chain amino acid sequence is not modified or is modified by amino to form-CONH 2 A group.
Preferably, Z is gammaglu.
Preferably, x is 2, y is 1, 2 or 3, and in particular, in the above amino acid sequence, x is 2, y is 1, or x is 2, y is 2, or x is 2, y is 3.
Preferably, in the amino acid sequence structure: n is any integer of 14-18, namely n is 14, 15, 16, 17 or 18.
According to a specific embodiment of the invention, a long-acting GLP-1 polypeptide analog has an amino acid sequence wherein Z is gamma Glu, x is 2, y is 1, 2 or 3, n is 18, and the sequence is as follows: ,
His-Xaa2-Glu-Gly-Thr-Phe-Thr-Ser-Xaa9-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys{(Gly) 2 -(Ser-Gly) y -γGlu-CO(CH 2 ) 18 CO 2 H}-Xaa21-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly。
preferably, the GLP-1 polypeptide analogue is any one of the following compounds:
compound 1 (SEQ ID NO. 1):
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Gly-Gly-Ser-Gly-γ-Glu-CO(CH 2 ) 18 CO 2 H)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly；
the abbreviation is: H-Aib-EGTFTSDVSSYLEGQAAK (GGSG-gamma-E-CO (CH) 2 ) 18 CO 2 H)EFIAWLVRGRG；
Compound 2 (SEQ ID NO. 2):
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Gly-Gly-Ser-Gly-Ser-Gly-γ-Glu-CO(CH 2 ) 18 CO 2 H)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly；
the abbreviation is: H-Aib-EGTFTSDVSSYLEGQAAK (GGSGSG-gamma-E-CO (CH) 2 ) 18 CO 2 H)EFIAWLVRGRG；
Compound 3 (SEQ ID NO. 3):
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Glu-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Gly-Gly-Ser-Gly-Ser-Gly-γ-Glu-CO(CH 2 ) 18 CO 2 H)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly；
the abbreviation is: H-Aib-EGTFTSEVSSYLEGQAAK (GGSGSG-gamma-E-CO (CH) 2 ) 18 CO 2 H)EFIAWLVRGRG；
Compound 4 (SEQ ID NO. 4):
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Glu-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Gly-Gly-Ser-Gly-Ser-Gly-γ-Glu-CO(CH 2 ) 18 CO 2 H)-Asp-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly；
the abbreviation is: H-Aib-EGTFTSEVSSYLEGQAAK (GGSGSG-gamma-E-CO (CH) 2 ) 18 CO 2 H)DFIAWLVRGRG；
Compound 5 (SEQ ID NO. 5):
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Gly-Gly-Ser-Gly-Ser-Gly-Ser-Gly-γ-Glu-CO(CH 2 ) 18 CO 2 H)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly；
the abbreviation is: H-Aib-EGTFTSDVSSYLEGQAAK (GGSGSGSG-gamma-E-CO (CH) 2 ) 18 CO 2 H)EFIAWLVRGRG；
Compound 6 (SEQ ID NO. 6):
His-(D-Ser)-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Gly-Gly-Ser-Gly-Ser-Gly-Ser-Gly-γ-Glu-CO(CH 2 ) 18 CO 2 H)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly；
the abbreviation is: hsEGTFTSDVSSYLEGQAAK (GGSGSGSG-gamma-E-CO (CH) 2 ) 18 CO 2 H)EFIAWLVRGRG；
Compound 7 (SEQ ID NO. 7):
His-(D-Ser)-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Gly-Gly-Ser-Gly-Ser-Gly-Ser-Gly-γ-Glu-CO(CH 2 ) 18 CO 2 H)-Gln-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly；
the abbreviation is: hsEGTFTSDVSSYLEGQAAK (GGSGSGSG-gamma-E-CO (CH) 2 ) 18 CO 2 H)QFIAWLVRGRG；
Compound 8 (SEQ ID NO. 8):
His-(D-Ser)-Glu-Gly-Thr-Phe-Thr-Ser-Glu-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Gly-Gly-Ser-Gly-Ser-Gly-Ser-Gly-γ-Glu-CO(CH 2 ) 18 CO 2 H)-Asp-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly。
the abbreviation is: hsEGTFTSEVSSYLEGQAAK (GGSGSGSG-gamma-E-CO (CH) 2 ) 18 CO 2 H)DFIAWLVRGRG；
A method for preparing a long-acting GLP-1 polypeptide analog according to an embodiment of the invention comprises the following steps:
step 1: synthesizing a main peptide resin corresponding to a main peptide chain of the long-acting GLP-1 polypeptide analogue according to an Fmoc/t-Bu strategy, wherein the main peptide chain is His-Xaa2-Glu-Gly-Thr-Phe-Thr-Ser-Xaa9-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Xaa21-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly;
and 2, step: on the basis of the main peptide resin, coupling a side arm structure corresponding to the long-acting GLP-1 polypeptide analogue according to an Fmoc/t-Bu strategy to obtain a polypeptide resin corresponding to the long-acting GLP-1 polypeptide analogue; wherein, the structure of the side arm is (Gly) x -(Ser-Gly) y -Z-CO(CH 2 ) n CO 2 H；
And step 3: adding a lysis solution into the polypeptide resin, carrying out a lysis reaction, removing full protection of the polypeptide, and extracting a crude product compound;
purifying the crude compound to obtain the long-acting GLP-1 polypeptide analogue.
According to a method of preparing a GLP-1 polypeptide analogue according to an embodiment of the invention,
in the step 2, coupling agents used are 1-hydroxybenzotriazole and N, N-diisopropylcarbodiimide, a solvent is N, N-dimethylformamide, and Fmoc groups are removed by using 20% piperidine/N, N-dimethylformamide solution;
in step 3, the lysis solution is composed of TFA, DODT, m-cresol and H 2 O is mixed according to the volume ratio of 92.5:2.5:2.5: 2.5; the crude compound extraction means comprises filtration, precipitation and/or methyl tert-butyl ether extraction.
In step 4, the purity of the obtained long-acting GLP-1 polypeptide analogue is more than 96 percent.
It is a further object of the present invention to provide a composition comprising a long-acting GLP-1 polypeptide analogue, further comprising a pharmaceutically acceptable carrier or adjuvant. For example, carriers capable of reducing drug degradation and loss, reducing side effects, such as micelles, microemulsions, gels, and the like; adjuvants refer to materials added to prepare the drug into a suitable dosage form, such as buffers, excipients for lyophilization, etc., and the pharmaceutical composition containing the polypeptide analogs of the present invention can be formulated as a solution or lyophilized powder for parenteral administration, which can be reconstituted with a suitable solvent or other pharmaceutically acceptable carrier prior to use, with liquid formulations typically being buffers, isotonic solutions, and aqueous solutions. The buffer solution can be phosphate buffer solution, the isotonic solution can be 0.9% sodium chloride solution, and the aqueous solution is directly dissolved by purified water.
As will be understood by those skilled in the art, the long-acting GLP-1 polypeptide analogue is used as an active ingredient, and is added with a pharmaceutically acceptable carrier and/or auxiliary material to prepare a pharmaceutical composition, which is suitable for various administration modes, such as oral administration, transdermal administration, intravenous administration, intramuscular administration, local administration, nasal administration and the like. Depending on the mode of administration employed, the pharmaceutical compositions of the polypeptide analogs of the present invention may be formulated in a variety of suitable dosage forms comprising at least one effective amount of the polypeptide analog of the present invention and at least one pharmaceutically acceptable carrier. Examples of suitable dosage forms are tablets, capsules, sugar-coated tablets, granules, oral solutions and syrups, ointments and patches for the skin surface, aerosols, nasal sprays, and sterile solutions for injection.
The amount of the pharmaceutical composition of the present invention may vary over a wide range and can be determined by one skilled in the art based on objective factors such as the type of disease, the severity of the condition, the weight of the patient, the dosage form, the route of administration, and the like.
Still another object of the present invention is to provide the use of the above-mentioned long-acting GLP-1 polypeptide analogues and compositions.
The invention obtains a series of GLP-1 polypeptide analogues, and researches the pharmacodynamic action of the series of medicaments. The GLP-1 receptor agonistic activity, the activity in the aspects of reducing blood sugar, blood fat and weight, treating diabetic nephropathy and the like of the synthesized series of polypeptide analogue medicines are evaluated, and the pharmacokinetics of the polypeptide analogue medicines are preliminarily researched. The result shows that compared with the somaglutide, the long-acting property of the pharmaceutical effect is far better than that of the somaglutide (the half-life period is 2 times or more than that of the somaglutide), and the pharmaceutical effect is also better than that of the somaglutide in treating and improving diabetic nephropathy.
Therefore, the long-acting GLP-1 polypeptide analogue has longer half-life, insulin-promoting activity and no adverse reaction, can be used for treating diabetes and obesity, and can be potentially used as a new generation of medicine for treating diabetes and obesity.
The application of the long-acting GLP-1 polypeptide analogue specifically comprises the following steps:
in the aspect of preparing medicaments for preventing or treating diabetes, in the aspect of preparing medicaments for preventing or treating obesity and in the aspect of preparing health-care products capable of reducing body weight.
The invention has the beneficial effects that:
the solution of polypeptide half-life and stability is the key to the design of polypeptide drugs and the possibility of drug development, and is also a significant scientific and core problem in the field of research. The development of the ultra-long-acting polypeptide drug molecule modification technology is a key and is also a bottleneck to be broken through internationally in the research of the field. According to the invention, through bioinformatics, structural biology, computer-aided design, structure-activity relationship research and the like, a site-specific side arm structure modification technology is developed, an ultra-long-acting polypeptide and protein drug molecule modification neck technology is broken through, the half-life period of a synthesized polypeptide analogue is greatly prolonged, and ultra-long-acting of a polypeptide drug is realized.
The parent peptide in the long-acting GLP-1 polypeptide analogue is a homologous polypeptide, the homologous polypeptide in the invention refers to a polypeptide which originally has the amino acid sequence of glucagon-like peptide (GLP-1) and somaglutide (Semaglutide), but one or more amino acid residues are replaced by different amino acid residues, and a side arm short peptide amino acid residue sequence is added in the structural sequence, the amino acid residues are conserved among each other, and the obtained polypeptide can be used for implementing the invention.
Specifically, we refer to "side arm" short peptide chains linked by amino acid substitutions at specific sites and specific sites described herein (Lys at position 20 in the amino acid sequence), namely: the site-specific side arm modification technology successfully breaks through the neck clamping technology modified by the ultra-long-acting polypeptide drug molecules. Compared with the positive medicine of the somaglutide without side arm modification, the polypeptide medicine designed by the invention greatly prolongs the action half-life period, realizes the ultra-long effect of the polypeptide medicine, and has the integral medicine action effect which is greatly superior to the positive medicine of the somaglutide.
In addition, the GLP-1 polypeptide analogs of the invention utilize lipophilic substituents to bind albumin in the blood, protecting it from enzymatic degradation, thereby increasing half-life. The GLP-1 polypeptide analogs of the invention stabilize the helical structure of the molecule via an intramolecular bridge, improving potency and/or selectivity for the glucagon-like peptide 1 receptor (GLP-1R).
The GLP-1 polypeptide analogue has high synthesis yield, good stability, easy amplification production and low cost.
Compared with the somaglutide, the long-acting property and the stability of the compound having the drug effect are far better than those of the somaglutide (the half-life period of the compound is 2 times or more than that of the somaglutide).
The GLP-1 polypeptide analogue is also superior to the somaglutide in treating and improving diabetes and nephropathy when the mass number is the same.
Meanwhile, the GLP-1 polypeptide analogue has better efficacy of reducing body weight, and the GLP-1 polypeptide analogue can be used for preventing body weight from increasing or promoting body weight from losing by causing food intake reduction and/or energy consumption increase, so that the GLP-1 polypeptide analogue can also be used for directly or indirectly treating other diseases caused by or characterized by overweight, such as treating and/or preventing obesity, morbid obesity, obesity-related inflammation, obesity-related gallbladder disease and sleep apnea caused by obesity, and the effect of the GLP-1 polypeptide analogue in the diseases can be due to the effect of the GLP-1 polypeptide analogue on body weight directly or indirectly or on other aspects of bodies except body weight.
Among the compounds synthesized by the embodiment of the invention, the compounds 2, 5, 6 and 7 have more excellent and more obvious glucose tolerance improving effect, longer drug effect and half-life period compared with the thaumatin, can obviously reduce the liver weight and epididymal fat content of mice, and are also better than the thaumatin in the aspects of improving the oral glucose tolerance (OGTT) and insulin resistance (ITT) of diabetic mice.
Abbreviations used in the present invention have the following specific meanings:
DCM is dichloromethane, DMF is N, N-dimethylformamide, HOBt is 1-hydroxybenzotriazole, fmoc is fluorenylmethoxycarbonyl, resin, FBS is fetal bovine serum, GLP-1R is glucagon-like peptide 1 receptor, GLP-1 is glucagon-like peptide, his is histidine, ser is serine, D-Ser is D-type serine, gln is glutamine, gly is glycine, glu is glutamic acid, ala is alanine, thr is threonine, lys is lysine, arg is arginine, tyr is tyrosine, asp is aspartic acid, trp is tryptophan, phe is phenylalanine, IIe is isoleucine, leu is leucine, cys is cysteine, pro is proline, val is valine, met is methionine, and Asn is asparagine. Aib is 2-aminoisobutyric acid, iva is isovaline.
Drawings
FIG. 1 is a graph of blood glucose monitoring at 24h and 48h after administration based on experimental animals in example 3; wherein:
FIG. 1A is a graph showing the change in blood glucose concentration within 120 minutes of intragastric gavage 24h after administration;
FIG. 1B is the area under the curve (AUC) calculated in FIG. 1A;
FIG. 1C is the change in blood glucose concentration within 120 minutes of intragastric gavage of glucose 48h after dosing;
FIG. 1D is the area under the curve (AUC) calculated in FIG. 1C;
FIG. 2 is a graph of blood glucose monitoring at 72h and 96h after administration based on experimental animals in example 3; wherein:
FIG. 2A is a graph of the change in blood glucose concentration within 120 minutes of intragastric gavage of glucose 72 hours after dosing;
FIG. 2B is the area under the curve (AUC) calculated in FIG. 2A;
FIG. 2C is the change in blood glucose concentration within 120 minutes of intragastric gavage glucose after 96h of administration;
FIG. 2D is the area under the curve (AUC) calculated in FIG. 2C;
FIG. 3 is a graph of body monitoring after administration of 8 week old male db/db diabetic mice in example 4, wherein:
FIG. 3A is a body weight monitor chart of a mouse according to example 4;
FIG. 3B is a graph showing blood glucose monitoring of mice in example 4;
FIG. 3C is a graph showing the monitoring of food intake of the mouse in example 4;
FIG. 4 is a serological index plot of the measurement of material draw after 6 weeks of treatment of 8 week-old db/db diabetic mice, wherein:
FIGS. 4A and 4B are mouse serum ALT and AST results, respectively, with p <0.05;
FIGS. 4C and 4D are mouse serum TG and T-CHO results, respectively, with p <0.05;
FIGS. 4E, 4F and 4G are graphs of mouse serum HDL-C, LDL-C and GHb results, respectively, with p <0.05;
FIG. 5 is a graphical representation of the week 6 physiological index of the mice dosed in example 4, wherein,
FIG. 5A is a graph of mouse liver weight (lever weight);
FIG. 5B is a graph of mouse liver index (lever/body weight);
FIG. 5C is a graph of mouse body weight (body weight);
FIG. 5D is a graph of mouse Body Mass Index (BMI);
FIG. 5E is a graph of epididymal fat weight (EAM weight) in mice;
FIG. 5F is a graph of epididymal fat index (EAM/body weight) in mice;
FIG. 6 is a graph of Oral Glucose Tolerance Test (OGTT) and insulin resistance test (ITT) tests in mice; wherein, the first and the second end of the pipe are connected with each other,
FIG. 6A is a graph of the OGTT results of the mice of example 4 administered at week 4;
FIG. 6B is a histogram of AUC corresponding to FIG. 6A;
FIG. 6C is a graph showing the ITT results at 5 weeks of administration of the mice in example 4;
FIG. 6D is a 5 week histogram of AUC dosing corresponding to FIG. 6C; p <0.05;
fig. 7 is a blood concentration profile of blood collected at different time periods after a single administration in 8-week-old SD rats, in which:
FIGS. 7A1 and 7A2 are the blood concentration curves of SD rat tail vein and subcutaneous injection of Somalutide, respectively;
fig. 7B1 and 7B2 are the blood concentration curves of SD rat tail vein and subcutaneous injection of compound 2, respectively;
fig. 7C1, 7C2 are plasma concentration curves of SD rat tail vein and subcutaneous injection of compound 5, respectively;
fig. 7D1, 7D2 are graphs of the blood concentration of SD rat tail vein and subcutaneous injection of compound 6, respectively;
fig. 7E1, 7E2 are plasma concentration curves of SD rat tail vein and subcutaneous injection of compound 7, respectively;
FIG. 8 shows the molecular formula and structure of fatty acid substituent.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
Materials:
all amino acids were purchased from jile biochemical, shanghai, somalutide from volume, peptides biology, inc, zhejiang, CAS No.:910463-68-2; all other reagents were analytical grade, purchased from Sigma, unless otherwise specified. Adopts Protein Technologies PRELUDE 6 channel polypeptide synthesizer, phenomenex Luna C 18 A preparative column (46mm. Times.250mm) was used for purifying the polypeptide, a high performance liquid chromatograph was a product of Thermo corporation, and mass spectrometry was performed using a Thermo liquid mass spectrometer.
The material and the method are as follows:
Boc-His (Trt) -OH, fmoc-Aib-OH was purchased from Gele, shanghai, and prepared as mono-tert-butyl eicosanedioate. The remaining amino acids were purchased from Chengdu Zhengyuan, inc., and the condensing agents were purchased from Suzhou Hao Van. All other reagents were analytical grade and solvents were purchased from Shanghai Tatan, unless otherwise specified. The centrifuge was purchased from Luxiang apparatus. 5.0m reverse phase C 18 Preparative columns (46mm X250mm) were used to purify the polypeptides. The high performance liquid chromatograph is a product of Saimerfi company. Mass spectrometry was performed using a Waters mass spectrometer.
EXAMPLE 1 Synthesis of Compound 5
Amino acid sequence of compound 5:
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Gly-Gly-Ser-Glym-γ-Glu-CO(CH 2 ) 18 CO 2 H)-Glu-Phe-Ile-Ala-Trp
-Leu-Val-Arg-Gly-Arg-Gly
the abbreviation is: H-Aib-EGT FTSDV SSYLEGAAK (GGSGSGSG-gamma-E-CO (CH) 2 ) 18 CO 2 H) EFIAW LVRGR G (acetate),
the method comprises the following steps:
step 1. Synthesis of Master peptide resin
Manual synthesis according to Fmoc/t-Bu strategy, scale of synthesis: 0.5mmol, the following main peptide resins were synthesized:
Boc-His-Aib-Glu(OtBu)-Gly-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Val-Ser(tBu)-Ser(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Gly-Gln(Trt)-Ala-Ala-Lys(Alloc)-Glu(OtBu)-Phe-Ile-Ala-Trp(Boc)-Leu-Val-Arg(pbf)-Gly-Arg(pbf)-Gly-Wang Resin。
(1): weighing 1.47 g Wang Resin (loading 0.47mmol/g, xian Langxi), adding into a reaction column, adding into N, N-Dimethylformamide (DMF), swelling for 30min, weighing Fmoc-Gly-OH:1.233g (6 eq), HOBT:0.672g (7.2 eq), DMAP:0.06g (0.72 eq) for use. The DMF was taken off, the resin was washed thoroughly with N, N-Dimethylformamide (DMF) 2 times, and the weighed material was added to the reaction column. An appropriate amount of DMF was added, nitrogen was added thereto and the mixture was stirred well, followed by addition of 0.83mL (7.8 eq) of N, N-Diisopropylcarbodiimide (DIC). And (5) reacting for 2h, and finishing the reaction. The reaction was taken off, washed 3 times with DMF and blocked for 4h by addition of acetic anhydride/pyridine (7,v/v). And (4) pumping the confining liquid, and washing 6 times by using DMF to obtain Fmoc-Gly-Wang Resin.
(2): fmoc-Gly-Wang Resin is used as a carrier, 1-Hydroxybenzotriazole (HOBT) and N, N-Diisopropylcarbodiimide (DIC) are used as coupling agents, N, N-Dimethylformamide (DMF) is used as a solvent, an Fmoc group is removed by a 20% Piperidine (Piperidine)/N, N-Dimethylformamide (DMF) solution (two times, 5min +7 min), and the coupling effect is monitored by ninhydrin in the coupling process. By performing manual feeding, fmoc-Arg (pbf) -OH, fmoc-Gly-OH, fmoc-Arg (pbf) -OH, fmoc-Val-OH, fmoc-Leu-OH, fmoc-Trp (Boc) -OH, fmoc-Ala-OH, fmoc-Ile-OH, fmoc-Phe-OH, fmoc-Glu (OtBu) -OH, fmoc-Lys (Alloc) -OH, fmoc-Ala-OH, fmoc-Ala-OH, fmoc-Ala-OH, fmoc-Gln (Trt) -OH, fmoc-Gly-OH, fmoc-Glu (OtBu) -OH, fmoc-Leu-OH, fmoc-Tyr (tBu) -OH, fmoc-Ser (tBu) -OH were connected by condensation reaction sequentially from C-terminus to N-terminus, fmoc-Ser (tBu) -OH, fmoc-Val-OH, fmoc-Asp (OtBu) -OH, fmoc-Ser (tBu) -OH, fmoc-Thr (tBu) -OH, fmoc-Phe-OH, fmoc-Thr (tBu) -OH, fmoc-Gly-OH, fmoc-Glu (OtBu) -OH, fmoc-Aib-OH, boc-His (Trt) -OH the above amino acids were dosed (5 eq relative to the synthesis scale) to give Boc-His-Aib-Glu (OtBu) -Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) - Leu-Glu (OtBu) -Gly-Gln (Trt) -Ala-Ala-Lys (Alloc) -Glu (OtBu) -Phe-Ile-Ala-Trp (Boc) -Leu-Val-Arg (pbf) -Gly-Arg (pbf) -Gly-Wang Resin.
There are several points to be explained:
1) The synthesis of Fmoc-Gly-Wang Resin has the disadvantages that the substitution degree of Wang Resin is low, the feeding amount of Fmoc-Gly-OH is large, otherwise, the substitution degree is low, and the material is wasted. Blocking with acetic anhydride/pyridine prevented the appearance of defective peptides.
2) In the following condensation reaction, the inventory of Fmoc protected amino acid, 1-Hydroxybenzotriazole (HOBT) and N, N-Diisopropylcarbodiimide (DIC) is 5 times, and the reaction time is 2 hours.
(3): removal of allyloxycarbonyl (Alloc)
Dichloromethane (DCM) was added to the resin, morpholine 0.5mL (12 eq) was added, and 0.173g of palladium tetratriphenylphosphine (0.3 eq) was weighed into the reaction column and reacted for 1h. After the reaction, the reaction solution was removed by suction, washed 3 times with N, N-Dimethylformamide (DMF) and 6 times with DCM. Obtaining a main peptide resin: boc-His-Aib-Glu (OtBu) -Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -Ala-Ala-Lys-Glu (OtBu) -Phe-Ile-Ala-Trp (Boc) -Leu-Val-Arg (pbf) -Gly-Arg (pbf) -Gly-Wang Resin.
Step 2, coupling the "side arm" structure:
coupling Fmoc-Gly-OH according to Fmoc/t-Bu strategy: adding Fmoc-Gly-OH, HOBT and a proper amount of N, N-Dimethylformamide (DMF) into the main peptide resin product, uniformly stirring with nitrogen, adding DIC, stirring with nitrogen for reaction for 2 hours, detecting the coupling effect with ninhydrin, and detecting the reaction to obtain the product with colorless transparency. And (3) pumping out reaction liquid, washing with N, N-Dimethylformamide (DMF) for 3 times, removing Fmoc groups (two times of 5min + 7min) by using 20% Piperidine (Piperidine)/N, N-Dimethylformamide (DMF) solution, washing with DMF for 6 times after removing Fmoc, sampling ninhydrin for detection, and developing color.
The operations are repeated to couple Fmoc-Gly-OH, fmoc-Ser (tBu) -OH, fmoc-Gly-OH, fmoc-Ser (tBu) -OH, fmoc-Gly-OH, fmoc-Ser (tBu) -OH, fmoc-Gly-OH, fmoc-Glu-OtBu and mono-tert-butyl didecylate in sequence. Obtaining Boc-His-Aib-Glu (OtBu) -Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -Ala-Lys (Gly-Gly-Ser (tBu) Gly-Ser (tBu) -Gly-Ser (tBu) -Gly-Glu-OtBu-ditert-butyl didecanedioate) -Glu (OtBu) -Phe-Ile-Ala-Trp (Boc) -Leu-Val-Arg (pbf) -Gly-Arg (pbf) -Gly-Wang Resin. Washing with N, N-Dimethylformamide (DMF) for 3 times, washing with Dichloromethane (DCM) for 3 times, shrinking with Methanol (Methanol) for 2 times, and vacuum drying to obtain dried polypeptide resin.
Step 3, removing polypeptide full protection
Lysis solution: TFA, DODT, m-cresol, H 2 O is mixed according to the volume ratio of 92.5:2.5:2.5: the mixture is prepared in advance according to the proportion of 2.5, and is frozen in a refrigerator for 2 hours.
To the dried polypeptide Resin Boc-His-Aib-Glu (OtBu) -Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -Ala-Ala-Lys (Gly-Gly-Ser (tBu) -Gly-Ser (tBu) -Gly-Ser (tBu) -Gly-Glu-OtBu-didecanedioic acid mono-tert-butyl ester) -Glu (OtBu) -Phe-Ile-Ala-Trp (Boc) -Leu-Val-Arg (pbf) -Gly-Arg (pbf) -Gly-Wang Resin was added lysate per 10mL of lysate/g polypeptide Resin, the lysate was warmed to room temperature, and the cleavage reaction was carried out for 3 hours. Filtering, washing the filter cake with a small amount of lysate for 3 times, and combining the filtrates. The filtrate was slowly poured into ice methyl tert-butyl ether with stirring. Standing for more than 2 hours until the precipitate is complete. The supernatant was removed, the precipitate was centrifuged, washed 3 times with methyl tert-butyl ether, centrifuged and the solid was blown dry with nitrogen. To obtain a crude compound His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys (Gly-Gly-Ser-Gly-Ser-Gly-Glu-eicosanedioic acid) -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly.
Step 4, refining and purifying crude compound
The crude compound obtained in step 2 was dissolved in Acetonitrile (ACN): h 2 O =1:2 (volume ratio), passing 5.0m of reverse phase C 18 Preparative HPLC purification was performed on a packed 46mm x 250mm column. With 45% acetonitrile/H 2 Starting with O (1% trifluoroacetic acid), the column was eluted with a gradient (increasing acetonitrile ratio at 0.33%/min) at a flow rate of 10mL/min for 6At 0min, fractions containing the polypeptide were collected, giving samples with HPLC purity greater than 90%. HPLC purification was repeated once starting with 31% acetonitrile/20 mM sodium dihydrogen phosphate in water and pH adjusted to 6.5 with 1M sodium hydroxide solution, using a gradient (0.33%/min increasing acetonitrile ratio) at a flow rate of 10mL/min, eluting the column for 60 minutes, collecting the polypeptide-containing fractions, and freeze-drying to obtain a purity of greater than 96.86% with a total yield of 15%.
Step 5. Product confirmation
Identifying the separated product polypeptide by liquid chromatography-mass spectrometry, and finding that the m/z value of the ion peak of the protonated molecule is as follows: 4397.16, target compound 5, theoretical compound 5 molecular weight 4397.87.
Synthesis of Compound 2
Since compound 2 differs from compound 5 by the sequence of the "side-arm" short peptide chain, the synthetic steps of compound 2 differ from compound 5 by step 2 coupling of the "side-arm" structure:
in the step, fmoc-Gly-OH, fmoc-Ser (tBu) -OH, fmoc-Gly-OH, fmoc-Ser (tBu) -OH, fmoc-Gly-OH, fmoc-Glu-OtBu and mono-tert-butyl didecanedioate are sequentially coupled. Obtaining Boc-His-Aib-Glu (OtBu) -Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -Ala-Ala-Lys (Gly-Gly-Ser (tBu) Gly-Ser (tBu) -Gly-Glu-OtBu-undecanedioic acid mono-tert-butyl ester) -Glu (OtBu) -Phe-Ile-Ala-Trp (Boc) -Leu-Val-Arg (pbf) -Gly-Wang Resin.
The purification of compound 2 and the confirmation of the product were carried out in the same manner as in compound 5, and the purity was more than 97.66%, and the total yield was 12%. The separated product was identified by LC-MS and the m/z values of the ion peaks of the protonated molecules were found to be: 4253.07 is target compound 2, and the theoretical molecular weight of compound 2 is 4253.74.
Based on the above synthesis steps, purification and product confirmation methods, the coupling order of the amino acids in the compound synthesis steps 1 and 2 was adjusted according to the difference in amino acids in the main peptide chain and the side arm "short peptide chain" of the compounds 1, 3, 4, 6, 7, 8, and finally the corresponding target product was synthesized, and the separated product was identified by liquid chromatography-mass spectrometry, the m/z value of the protonated molecular ion peak (the actual value in table 1) was confirmed, and the actual value was compared with the theoretical value of molecular weight to confirm that the synthesized and purified product was the target product, and the theoretical value of molecular weight, the actual value of liquid chromatography-mass spectrometry, the sequence and the molecular formula of the compounds 1 to 8 were given in table 1, respectively.
TABLE 1 Long-acting GLP-1 polypeptide analogue amino acid sequence table and liquid chromatography-mass spectrometry combined identification result
Figure BDA0003170024560000161
Figure BDA0003170024560000171
EXAMPLE 2 evaluation of agonistic Activity of Compounds 1-8 and Somaglutide on GLP-1R (glucagon-like peptide 1 receptor)
The agonistic activity of GLP-1R was determined for compounds 1-8 and somaglutide in a GLP-1R-Luciferase-HEK293 cell model (cell line constructed in this laboratory).
First, cells were digested in 96-well plates (medium containing 10% FBS, GLP-1R-Luciferase-HEK293:20000cell/well, 100. Mu.L); after 36h, the culture medium in the 96-well plate is discarded, and 90 mu L of serum-free culture medium is added; after 6h, serial concentrations (0.01, 0.1, 1, 10, 100, 1000, 10000, 100000, 1000000, 10000000, 100000000 pM) of polypeptide drugs (8 polypeptide analogs and somaglutide) were prepared in serum-free medium, 10 μ L (i.e. diluted 10-fold) was added to each well, and the cells were incubated for 5h; adding 100 mu L of cell lysate into each well, cracking on ice for 10min, then shaking uniformly, taking 2 mu L of lysate, adding into a white board of a 384 enzyme-labeling instrument, adding 10 mu L of firefly luciferase reaction solution, reading, adding 10 mu L of renilla luciferase reaction solution, and reading; data processing, the number of the firefly luciferase reading is divided by the Renilla luciferase reading, and the blank value is subtracted to obtain the activation times at different concentrations.
TABLE 2 EC of Compounds 1-8 with Somuramyl peptide agonizing GLP-1R 50
EC 50
Somazutide 222.2pM
Compound
1 699.1pM
Compound
2 64.73pM
Compound
3 1003.7pM
Compound
4 1349.9pM
Compound
5 146.3pM
Compound
6 203.5pM
Compound
7 302.4pM
Compound
8 1599.2pM
From experimental knotAs can be seen, compounds 1-8 of the present invention all activated GLP-1R, and compounds 2, 5, 6 and 7 had better agonistic activity against GLP-1R (Table 2), wherein half maximal effect concentration (hereinafter abbreviated as EC) of compounds 2, 5 50 That is, a concentration that causes 50% of the maximal effect) is lower than thaumareuptade, indicating that the agonistic activity towards GLP-1R is superior to thaumareuptade, while the agonistic activity towards GLP-1R of compounds 6, 7 is comparable to thaumareuptade.
EXAMPLE 3 Effect of Compounds 1-8 and Somalitide on oral glucose tolerance (OGTT)
Male C57BL/6J mice (Experimental animals center, zhongshan university) of around 8 weeks of age were housed for one week in acclimation and randomly grouped into groups of 8 per group according to similar blood glucose (evaluation of blood samples taken from the tail tip).
The compounds 1-8 of the present invention (corresponding to numbers 1-8 in the figures) and somaglutide (corresponding to semaglutide in the figures) were administered subcutaneously at a dose of 120ug/kg, and the control group was administered with the same dose of PBS. ddH for intragastric glucose 2 O is prepared into stock solution with the concentration of 0.5g/mL and is stored at normal temperature. Mice were fasted for 8h before gavage, gavage glucose at a dose of 2.5g/kg at 24h, 48h, 72h and 96h post-dose, respectively, and blood glucose was measured at t =0min, t =15min, t =30min, t =60min, t =90min and t =120 min. The data were processed using software GraphPadPrism to generate a line graph of blood glucose changes and calculate the area under the curve to generate an AUC plot, the results of which are shown in fig. 1 and fig. 2.
According to the AUC (area under concentration-time curve) counted by the OGTT curve, the bioavailability is high when the AUC is large, and the bioavailability is low when the AUC is not large. Wherein in fig. 1 and 2: p <0.05; * *: p <0.01; * **: representing p <0.001.
As can be seen from fig. 1A and B, the sumatriptan and compounds 1-8 significantly reduced AUC compared to vehicle (PBS) after 24h administration, indicating that sumatriptan and compounds 1-8 have significant glucose tolerance.
As can be seen from fig. 1C, D and fig. 2, the effect of somaglutide on AUC did not differ significantly from vehicle (PBS) after 48h, 72h, 96h of administration, indicating that somaglutide has failed to improve glucose tolerance. After 48h, 72h, 96h of administration, compounds 2, 5, 6 and 7 still significantly reduced AUC compared to PBS group, and thus improved glucose tolerance, and thus, compounds 2, 5, 6 and 7 were all superior to somaglutide in improving glucose tolerance in mice.
As can be seen from the above, compounds 1 to 8 of the present invention all have the effect of improving glucose tolerance in mice to different degrees compared to vehicle (PBS), wherein compounds 2, 5, 6 and 7 exhibit more excellent and significant glucose tolerance improvement effect in 4 OGTT curve periods (24, 48, 72, 96 h), and the results also indicate that compounds 1 to 8, especially compounds 2, 5, 6 and 7 exhibit more excellent and significant long-acting glucose lowering effect in 4 OGTT curve periods (24, 48, 72, 96 h) relative to thaumautide.
EXAMPLE 4 therapeutic Effect of Compounds 2, 5, 6, 7 and Somalutide on diabetes in diabetic mice
48 male Lepr db/db mice (db/db) at 8 weeks of age and 8 littermate normal mice (WT) were purchased from Nanjing university-Nanjing biomedical research institute.
A db/db mouse diabetes model was obtained (purchased from Nanjing university-Nanjing biomedical research institute, mice about 8 weeks, and blood glucose and body weight were measured to ensure smooth performance of subsequent experiments), db/db mice were randomly divided into 6 groups according to blood glucose ( compounds 2, 5, 6, 7 and somatid, physiological saline group), each group had 8 mice, and there was no difference in basal body weight and blood glucose. Each group of mice was injected subcutaneously every other day with compounds 2, 5, 6, 7 (120. Mu.g/kg), somaglutide (120. Mu.g/kg) and saline (WT group and db/db group), respectively. After each administration of the mice, fasting for 6h every other day to measure the blood sugar and body weight of the mice; the water intake and food intake were measured every 7 days. OGTT was measured at week 4 of dosing, insulin tolerance (ITT) at week 5, and samples taken at week 6, and various serological and physiological indices were examined. The monitoring results of blood sugar, body weight, water intake and food intake of the mice are shown in figure 3, the serological indexes after material taking are shown in figure 4, and the physiological indexes are shown in figure 5.
A model of type 2 diabetes characterized by: obesity, insulin resistance, hyperglycemia, dyslipidemia, liver steatosis, and the like. Oral Glucose Tolerance Test (OGTT) and insulin resistance test (ITT) were performed at 4 and 5 weeks of treatment of diabetic mice with compounds 2, 5, 6, 7 and somaglutide, respectively, and the results are shown in fig. 6.
FIG. 3 is a graph of post-administration body monitoring of medium 8 week old male db/db diabetic mice, wherein normal saline, compound 2 (120. Mu.g/kg), compound 5 (120. Mu.g/kg), compound 6 (120. Mu.g/kg), compound 7 (120. Mu.g/kg) and Somalutide (120. Mu.g/kg) were injected subcutaneously for 6 weeks, respectively; body weight and blood glucose of mice were measured every 3 days after 6h fasting (3A and 3B), and food intake of mice was measured every 7 days (3C), wherein: p <0.05; * *: represents p <0.01; * **: representing p <0.001.
The results in fig. 3 (a, C) show that compounds 2, 5, 6, and 7 significantly reduced the food intake of mice compared to db/db group, thereby reducing the weight of mice, and the weight reduction effect was superior to thaumatin.
The results in fig. 3B show that compounds 2, 5, 6, 7 and the positive control drug somaglutide significantly reduced fasting plasma glucose in db/db mice compared to db/db group, indicating that these drugs had significant hypoglycemic effects, blood glucose had decreased to normal levels by week 1 and thereafter blood glucose was relatively stable and superior to somaglutide.
Fig. 4 (a, B) shows that compounds 2, 5, 6 and 7 are also comparable to somaglutide in terms of liver protection function.
Glycated hemoglobin (GHb) can be used as a control index reflecting that the diabetic obtains blood sugar for a long period of time (4-10 weeks), the glycated hemoglobin is increased due to the long-term poor control of the blood sugar, so the glycated hemoglobin measurement is helpful for control, and has an important role in the study of peripheral vascular and cardiovascular complications of diabetes, and the experimental results in fig. 4G show that compounds 2, 5, 6 and 7 have a significant effect of reducing glycated hemoglobin and are superior to thaumatin.
The results in fig. 5E show that compounds 2, 5, 6 and 7 can significantly reduce the liver weight and epididymal fat content of mice, and are superior to thaumatin.
The results in fig. 6 show that compounds 2, 5, 6 and 7 are superior to the positive control drug somaglutide in improving oral glucose tolerance (OGTT) and insulin resistance (ITT) in diabetic mice, as seen in the results.
Example 5 pharmacokinetic study of Compounds 2, 5, 6 and 7 and Somaloutide in SD rats
SD rats (Experimental animal center of Zhongshan university) of about 8 weeks old are bred for one week to adapt to the environment, and the male and female animals are randomly grouped according to the body weight, and 6 animals (male and female animals) are grouped in each group for 5 groups.
In this example, compounds 2, 5, 6 and 7 and somaglutide were administered at a dose of 50ug/kg, a volume of 2mL/kg, a concentration of 60ug/mL, and a vehicle of physiological saline, subcutaneously and in the tail vein, respectively.
The rats in the single tail vein administration group had blood samples collected through jugular veins before (0 min) and 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 24h, 36h, 48h, 72h, 4d, 5d, 6d, 7d, 8d, 9d, 10d after administration, and the collection amount was about 0.2mL at each time point. The rats in the single subcutaneous injection group had blood samples collected via jugular vein before (0 min) and 10min, 20min, 30min, 1h, 2h, 4h, 6h, 8h, 24h, 36h, 48h, 72h, 4d, 5d, 6d, 7d, 8d, 9d, 10d after administration, with a collection volume of about 0.2mL at each time point. Placing in a container containing anticoagulant K 2 EDTA in EP tubes, and centrifugation (3500 g, 10min) at 2-8 ℃ within 1 hour after blood collection, and the plasma separated after centrifugation was filled in labeled EP tubes, and the drug concentrations of compounds 2, 5, 6, 7 and Somalutide in the plasma were determined by LC-MS/MS analysis. Data processing pharmacokinetic parameters were calculated using a non-compartmental model in WinNonlin 6.4 software.
As can be seen from the results of the experiment in FIG. 7, after a single subcutaneous injection of compounds 2, 5, 6 and 7 (50. Mu.g/kg), the absorption in rats was slow and the time to peak T was observed max All are about 24h, half-life period t 1/2 On average 14.99h, 15.4h, 16.6h and 15.42h, respectively, compounds 2, 5, 6 and 7 were all higher than thaumatin (7.87 h). Half-life t after a single intravenous injection of Compounds 2, 5, 6 and 7 (50. Mu.g/kg) 1/2 The average time is 14.49h, 15.2h, 16.2h and 15.1h respectively, and the average time is superior to that of the somaglutide (the average time is 8 h).
The above description is only for the specific embodiments of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily think of the changes or substitutions within the technical scope of the present invention, and shall cover the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Sequence listing
<110> Qingdao Borui scientific & technological Limited
<120> long-acting GLP-1 polypeptide analogue, preparation method and application thereof
<141> 2021-07-19
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 31
<212> PRT
<213> Artificial Synthesis ()
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa=Aib
<220>
<221> UNSURE
<222> (2)..(2)
<223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu.
<400> 1
His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
20 25 30
<210> 2
<211> 31
<212> PRT
<213> Artificial Synthesis ()
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa=Aib
<220>
<221> UNSURE
<222> (2)..(2)
<223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu.
<400> 2
His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
20 25 30
<210> 3
<211> 31
<212> PRT
<213> Artificial Synthesis ()
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa=Aib
<220>
<221> UNSURE
<222> (2)..(2)
<223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu.
<400> 3
His Xaa Glu Gly Thr Phe Thr Ser Glu Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
20 25 30
<210> 4
<211> 31
<212> PRT
<213> Artificial Synthesis ()
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa=Aib
<220>
<221> UNSURE
<222> (2)..(2)
<223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu.
<400> 4
His Xaa Glu Gly Thr Phe Thr Ser Glu Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Asp Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
20 25 30
<210> 5
<211> 31
<212> PRT
<213> Artificial Synthesis ()
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa=Aib
<220>
<221> UNSURE
<222> (2)..(2)
<223> The 'Xaa' at location 2 stands for Gln, Arg, Pro, or Leu.
<400> 5
His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
20 25 30
<210> 6
<211> 31
<212> PRT
<213> Artificial Synthesis ()
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> D-Ser
<400> 6
His Ser Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
20 25 30
<210> 7
<211> 31
<212> PRT
<213> Artificial Synthesis ()
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> D-Ser
<400> 7
His Ser Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Gln Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
20 25 30
<210> 8
<211> 31
<212> PRT
<213> Artificial Synthesis ()
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> D-Ser
<400> 8
His Ser Glu Gly Thr Phe Thr Ser Glu Val Ser Ser Tyr Leu Glu Gly
1 5 10 15
Gln Ala Ala Lys Asp Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
20 25 30

Claims (5)

1. A long-acting GLP-1 polypeptide analog, wherein the amino acid sequence of said long-acting GLP-1 polypeptide analog is as follows: his-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys (Gly-Gly-Ser-Gly-Ser-Gly- γ -Glu-CO (CH) 2 ) 18 CO 2 H)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly。
2. A method for preparing a long-acting GLP-1 polypeptide analogue according to claim 1, comprising the steps of:
step 1: synthesizing a main peptide resin corresponding to a main peptide chain of the long-acting GLP-1 polypeptide analogue according to the Fmoc/t-Bu strategy, wherein the main peptide chain is His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly;
step 2: on the basis of the main peptide resin, coupling a side arm structure corresponding to the long-acting GLP-1 polypeptide analogue according to an Fmoc/t-Bu strategy to obtain a polypeptide resin corresponding to the long-acting GLP-1 polypeptide analogue; wherein the structure of the side arm is Gly-Gly-Ser-Gly-Ser-Gly-Ser-Gly-gamma-Glu-CO (CH) 2 ) 18 CO 2 H；
And step 3: adding a lysis solution into the polypeptide resin, carrying out a cleavage reaction, removing full protection of the polypeptide, and extracting a crude product compound;
and 4, step 4: purifying the crude compound to obtain the long-acting GLP-1 polypeptide analogue.
3. The method for producing a long-acting GLP-1 polypeptide analog according to claim 2,
in the step 2, coupling agents used are 1-hydroxybenzotriazole and N, N-diisopropylcarbodiimide, a solvent is N, N-dimethylformamide, and Fmoc groups are removed by using 20% piperidine/N, N-dimethylformamide solution;
in step 3, the lysis solution is composed of TFA, DODT, m-cresol and H 2 O is mixed according to a volume ratio of 92.5:2.5:2.5: 2.5; the crude compound extraction means comprises filtration, precipitation and/or methyl tert-butyl ether extraction.
4. A composition comprising a long-acting GLP-1 polypeptide analogue of claim 1 and a pharmaceutically acceptable carrier or adjuvant.
5. Use of a long-acting GLP-1 polypeptide analogue of claim 1 for the preparation of a medicament for the treatment of diabetes;
alternatively, the long-acting GLP-1 polypeptide analogue is used for preparing a medicament for treating obesity.
CN202110815583.3A 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof Active CN113429471B (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202110815583.3A CN113429471B (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof
CN202211555764.8A CN116554299A (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof
CN202211555750.6A CN116410297A (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof
PCT/CN2021/107770 WO2023000240A1 (en) 2021-07-19 2021-07-22 Long-acting glp-1 polypeptide analogue, and preparation method therefor and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110815583.3A CN113429471B (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202211555750.6A Division CN116410297A (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof
CN202211555764.8A Division CN116554299A (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113429471A CN113429471A (en) 2021-09-24
CN113429471B true CN113429471B (en) 2022-12-23

Family

ID=77761113

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202211555750.6A Pending CN116410297A (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof
CN202110815583.3A Active CN113429471B (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof
CN202211555764.8A Pending CN116554299A (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211555750.6A Pending CN116410297A (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211555764.8A Pending CN116554299A (en) 2021-07-19 2021-07-19 Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof

Country Status (2)

Country Link
CN (3) CN116410297A (en)
WO (1) WO2023000240A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114716533B (en) * 2022-04-12 2023-04-14 北京惠之衡生物科技有限公司 Acylated long-acting GLP-1 derivative
CN115947822B (en) * 2022-07-04 2023-08-18 北京惠之衡生物科技有限公司 Long-acting acylated insulin derivative, and pharmaceutical composition and application thereof
CN117756913A (en) * 2022-11-07 2024-03-26 内蒙古博睿精创科技有限公司 Novel long-acting polypeptide compound, composition and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8614182B2 (en) * 2009-07-30 2013-12-24 Jiangsu Hansoh Pharmaceuticals Co., Ltd. GLP-1 analogues and their pharmaceutical salts and uses
WO2013029279A1 (en) * 2011-09-03 2013-03-07 深圳市健元医药科技有限公司 Novel glp-i analogue, preparation method and use thereof
AR104932A1 (en) * 2015-06-22 2017-08-23 Lilly Co Eli GLUCAGON AND PEPTIDE-1 CO-AGONIST COMPOUNDS SIMILAR TO GLUGACON (GLP-1)
US11130794B2 (en) * 2017-07-19 2021-09-28 Novo Nordisk A/S Bifunctional compounds
CN111253475B (en) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 GLP-1 agonist polypeptide compound and salt thereof, and synthesis method and application thereof
CN112110981B (en) * 2020-09-23 2021-06-25 深圳深创生物药业有限公司 Preparation method of polypeptide containing long-chain fatty diacid side chain
CN112898405B (en) * 2021-01-22 2023-02-28 深圳市图微安创科技开发有限公司 Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications

Also Published As

Publication number Publication date
CN116554299A (en) 2023-08-08
WO2023000240A1 (en) 2023-01-26
CN116410297A (en) 2023-07-11
CN113429471A (en) 2021-09-24

Similar Documents

Publication Publication Date Title
AU2015321161B2 (en) Oxyntomodulin analogue
CN113429471B (en) Long-acting GLP-1 polypeptide analogue, and preparation method and application thereof
CN112409460B (en) GLP-1/glucagon receptor dual agonist and application thereof
CN111253475B (en) GLP-1 agonist polypeptide compound and salt thereof, and synthesis method and application thereof
CN106928341B (en) Fixed-point mono-substituted pegylated Exendin analogue and preparation method thereof
KR20040070237A (en) Insulin Molecule Having Protracted Time Action
CN106661096B (en) Novel exenatide analogue and application thereof
CN112898406B (en) GLP-1 analogue peptide modified dimer with different configurations and application of preparation method thereof in treatment of type II diabetes
AU2024203093A1 (en) Polypeptide compounds and use thereof in the prevention or treatment of diabetes or diagnostic compounds
CN105968186B (en) Glucagon (Glu) analogue with long-acting effect and application thereof
KR20230008846A (en) Polypeptide derivatives with dual receptor agonism and their uses
CN110759991B (en) Gemfibrozil-xenopus laevis glucagon-like peptide-1 derivative and application thereof
CN113754752B (en) Polypeptide and preparation method and application thereof
CN116514952B (en) GLP-1 analogues and application thereof
CN115232200B (en) Long-acting Exendin-4 analogue and application thereof
CN117756913A (en) Novel long-acting polypeptide compound, composition and application thereof
CN115073582A (en) Polypeptide compound and application thereof in preventing or treating diabetes or diabetic complications

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 017299 1701, Floor 17, Dongfang Building, Altan Xire, Ejin Horo Banner Banner, Ordos City, Inner Mongolia

Patentee after: Inner Mongolia Borui Jingchuang Technology Co.,Ltd.

Address before: 266600 Room 101, No. 14, Zhenxing Road, Nanshu Town, Laixi City, Qingdao City, Shandong Province

Patentee before: Qingdao Borui Jingchuang Technology Co.,Ltd.